Insulin Degludec
Insulin degludec (desB30, acylated ultra-long-acting insulin analog)
50 Amino Acids · MW: 6103.9 Da
Amino Acids
50
Molecular Weight
6103.9 Da
Half-life
More than 25 hours
Research Score
4.8
Studies
7000
Storage
Store lyophilized at -20°C, reconstituted at 2-8°C
What is Insulin Degludec?
An ultra-long-acting insulin analog designed with a fatty-acid side chain to form a slow-release depot. It is valued for very flat pharmacokinetics and flexible once-daily basal dosing.
Key Benefits & Mechanisms
Ultra-long basal coverage
Lower day-to-day variability
Reduced nocturnal hypoglycemia
Flexible dosing time
Research Summary
Studies highlight prolonged action and lower glycemic variability compared with many other basal insulins. It is frequently used in research on ultra-long basal coverage and hypoglycemia reduction.
Related Peptides
Insulin Lispro
Insulin lispro (B28-Lys, B29-Pro human insulin analog)
A rapid-acting insulin analog with a reversed B28/B29 sequence that speeds absorption after subcutaneous injection. It is used to reduce postprandial hyperglycemia and to support flexible mealtime insulin strategies.
Diabetes & MetabolicInsulin Aspart
Insulin aspart (B28-Asp human insulin analog)
A rapid-acting insulin analog with an amino-acid substitution at B28 that promotes faster absorption after injection. It is widely used to blunt postprandial glucose excursions in diabetes research and clinical practice.
Diabetes & MetabolicInsulin Glargine
Insulin glargine (A21Gly,B31Arg,B32Arg human insulin analog)
A long-acting basal insulin analog engineered for slow release from the subcutaneous depot. It provides relatively flat day-long insulin coverage and is used to control fasting glucose.
Diabetes & MetabolicExendin-4
Exendin-4 (synthetic exenatide)
A 39-amino-acid GLP-1 receptor agonist originally isolated from Heloderma saliva. It enhances glucose-dependent insulin secretion and shows strong beta-cell anti-apoptotic activity in preclinical diabetes models.
Diabetes & Metabolic